{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-079871","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-07-01T20:15:26+00:00","discovered_at":"2026-07-01T20:17:00.439392+00:00","generated_at":"2026-07-01T20:17:24.201603+00:00","sec_items":["1.01","1.02","2.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cumberland closes $100M sale of branded products to Apotex; retains ifetroban pipeline","bullets":["Sold Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ for $100M cash.","Over 99% of shareholder votes supported the transaction.","Company retains ifetroban candidates for Duchenne, systemic sclerosis, IPF, cancer metastasis.","Terminated $5.3M Pinnacle Bank credit facility; repaid in full.","Pro forma shows ~$110M cash, no product revenue, net loss from continuing ops."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-079871","json":"https://secwatch.observer/filing/0001104659-26-079871.json","markdown":"https://secwatch.observer/filing/0001104659-26-079871.md","text":"https://secwatch.observer/filing/0001104659-26-079871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/0001104659-26-079871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/tm2619330d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T20:17:24.201603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c868e1ad94","claim":"James L. Herman departed as Vice President Trade & Distribution and Corporate Compliance Officer at CUMBERLAND PHARMACEUTICALS INC.","evidence_excerpt":"Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/0001104659-26-079871-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Vice President Trade & Distribution and Corporate Compliance Officer"}],"fact_type":"executive_change"},{"claim_id":"f6378ab00b","claim":"Chris T. Bitterman departed as Vice President Sales & Marketing at CUMBERLAND PHARMACEUTICALS INC.","evidence_excerpt":"Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/0001104659-26-079871-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Vice President Sales & Marketing"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}